KRAS and non-small cell lung carcinoma: KRAS is the predominantly mutated RAS isoform (85%) and also the most frequent oncogene in NSCLC [8]. KRAS fosters tumour growth via several mechanisms, including by upregulating rate-limiting enzymes involved in amino acid, fatty acid, or nucleotide biosynthesis, and by stimulating scavenging pathways, such as macropinocytosis and autophagy [9,10], which, in turn provide building blocks for the anabolic routes, also maintaining the energy levels and the cell’s redox potential [11].